Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + epidoxorubicin + cyclophosphamide
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This drug is a combination chemotherapy regimen consisting of three agents: 5-fluorouracil, epidoxorubicin (an analogue of doxorubicin), and cyclophosphamide. It is most commonly referred to as the CAF regimen when doxorubicin is used, but can also be formulated with epidoxorubicin in place of doxorubicin. Each component has a distinct mechanism: - 5-fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and repair. - Epidoxorubicin (epirubicin) is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and repair. - Cyclophosphamide is an alkylating agent that crosslinks DNA strands, leading to cell death. The combination attacks cancer cells through multiple mechanisms to maximize cytotoxicity. This regimen has been widely used as adjuvant or neoadjuvant therapy for breast cancer at high risk for recurrence[1][3][4].
- Brand names
- Adrucil
- Other names
- CAF
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + epidoxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + epidoxorubicin + cyclophosphamide.